Summary of AGL Q2 2026 Earnings Call

1Key Financial Results and Metrics

Membership: Medicare Advantage membership increased to 437,000, up from 426,000 in Q1 2026 but down from 498,000 in Q2 2025. ACO REACH membership rose to 112,000 from 110,000 in Q1 2026.

Revenue: Approximately $1.5 billion for Q2 2026, up from $1.4 billion in Q2 2025.

Medical Margin: Reported at $197 million, a significant improvement from a loss of $53 million in Q2 2025.

Adjusted EBITDA: $70 million, compared to a negative $83 million in the same quarter last year.

Cash Position: Ended the quarter with $257 million in cash and marketable securities.

2Strategic Updates and Business Highlights

New CEO Tim O'Rourke emphasized a focus on strengthening physician partnerships and enhancing operational execution.

Agilon is advancing clinical, quality, and AI initiatives to improve patient outcomes and reduce costs.

The Burden of Illness program showed strong performance, contributing to improved medical cost trends.

Clinical pathways for chronic conditions like CHF, COPD, and dementia are being developed and expanded.

Agilon is positioned to capitalize on the shift toward value-based care, with promising results from the ACO REACH program, which reported $229 million in gross savings.

3Forward Guidance and Outlook

Full-Year 2026 Guidance: Revenue is now expected to be approximately $5.8 billion, medical margin at $485 million, and adjusted EBITDA at $85 million.

Q3 2026 Guidance: Anticipated revenue of approximately $1.46 billion, medical margin of about $110 million, and break-even adjusted EBITDA.

The guidance reflects confidence in ongoing operational execution, improved data visibility, and favorable medical expense trends.

4Bad News, Challenges, or Points of Concern

Membership decline year-over-year in Medicare Advantage raises concerns about growth sustainability.

The company is cautious about future growth, particularly in new markets, emphasizing a disciplined approach to contracting and profitability.

There is still variability in performance across physician groups, which the company aims to address.

The macroeconomic environment remains uncertain, with potential pressures on medical cost trends.

5Notable Q&A Insights

Management confirmed that the favorable prior year development (PYD) of $22 million is a key factor in the current financial results but may not be a recurring benefit.

Discussions with payers for 2027 contracts are ongoing, with a focus on profitability and reducing exposure to Part D.

The company is optimistic about growth opportunities within existing markets, particularly through converting care coordination fee contracts to full risk.

The enhanced data pipeline now includes over 80% of payers, which is expected to improve risk adjustment and clinical outcomes.

Future clinical pathways are being prioritized, with a focus on early identification and intervention for chronic conditions. Overall, Agilon Health's Q2 2026 results reflect strong operational performance and strategic initiatives aimed at enhancing value-based care, though challenges in membership growth and market variability remain.